2025 · Abstract/Manuscript · GSK
President of Headwater Science
M. Alan Brookhart, PhD
Alan is a biostatistician and an epidemiologist who has spent the last 15 years developing and applying epidemiological and statistical methods for studies using real-world healthcare data. He has more than 200 publications in leading journals in medicine, biostatistics, and epidemiology. In 2021 Target RWE acquired his company NoviSci, Inc., a company that built and applied analytic software and visualization tools for RWE generation.
Alan is also a Professor in the Department of Population Health Sciences at Duke University, an Adjunct Professor at UNC Chapel Hill, and an Honorary Professor of Clinical Epidemiology at the University of Aarhus, Denmark. Previously Alan was on faculty at Harvard Medical School and was also a co-founder and chair of the scientific advisory board of RxAnte, Inc., a provider of widely used predictive analytics for decision support. Alan is a member of many scientific advisory groups, review panels, and editorial boards.

Publications
17
Total Publications
2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Propensity Score Methods for Confounding Control in Observational Studies of Therapeutics for COVID-19 Infection
Read more →2024 · Oral Presentation · Yes · Methods/Pharmacoepi
Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study
Read more →2024 · Poster Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Addressing RWE Challenges in Real-Time: The 'Clean Room Committee' Approach
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: A narrative review
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study
Read more →2022 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
In-Hospital Treatment Patterns Among Patients Hospitalized with COVID-19 in the United States
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Discharged Where? The Importance of Understanding Discharge Dispositions When Estimating In-Hospital Mortality
Read more →2022 · Oral Presentation · Amgen Inc. · Methods/Pharmacoepi
Fracture Risk Estimation in Post-menopausal Women: A Comparison of Machine Learning Methods and Software Systems
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Risk Factors for Mortality and Intensive Care Requirements Among Pediatric Patients Hospitalized with COVID-19 in the United States
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
The Effect of Remdesivir for The Treatment of COVID-19 on Mortality Among Hospitalized Patients
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Negative Control Outcomes to Assess the Comparability of Biologics versus Small-molecule Therapeutics for Osteoporosis: Considerations for Differential Non-adherence
Read more →2020 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Who are we missing? Underrepresentation of data sources used for pharmacoepidemiology research in the United States
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Using Instrumental Variables to Address Bias from Unobserved Confounders
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Informative censoring by health plan disenrollment among commercially insured adults
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi